| abstract |
Combination of a first component which is a 5-HT reuptake inhibitor and a second component which is a selective 5-HT1A antibody of formula (I) wherein R1 is n-propyl or cyclobutyl, R2 is isopropyl, tertiary butyl, cyclobutyl, cyclopentyl or cyclohexyl, R 3 is hydrogen, R 4 is hydrogen or methyl, such as the (R) -enantiomer in free base form or a pharmaceutically acceptable salt thereof, a process for its preparation, a pharmaceutical formulation comprising said combination, its use to improve the treatment of emotional disorders and a kit containing of said combination |